RT Journal Article
SR Electronic
T1 Acute COVID-19 severity and 16-month mental morbidity trajectories in patient populations of six nations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.13.21267368
DO 10.1101/2021.12.13.21267368
A1 Magnúsdóttir, Ingibjörg
A1 Lovik, Anikó
A1 Unnarsdóttir, Anna Bára
A1 McCartney, Daniel
A1 Ask, Helga
A1 Kõiv, Kadri
A1 Nordahl Christoffersen, Lea Arregui
A1 Johnson, Sverre Urnes
A1 McIntosh, Andrew
A1 Kähler, Anna K.
A1 Campbell, Archie
A1 Hauksdóttir, Arna
A1 Fawns-Ritchie, Chloe
A1 Erikstrup, Christian
A1 Helenius, Dorte
A1 Altschul, Drew
A1 Thordardottir, Edda Bjork
A1 Eyþórsson, Elías
A1 Frans, Emma M.
A1 Tómasson, Gunnar
A1 Jónsdóttir, Harpa Lind
A1 Rúnarsdóttir, Harpa
A1 Hjalgrim, Henrik
A1 Harðardóttir, Hrönn
A1 González-Hijón, Juan
A1 Banasik, Karina
A1 Dinh, Khoa Manh
A1 Lu, Li
A1 Milani, Lili
A1 Trogstad, Lill
A1 Didriksen, Maria
A1 Ebrahimi, Omid V.
A1 Sullivan, Patrick F.
A1 Magnus, Per Minor
A1 Shen, Qing
A1 Nesvåg, Ragnar
A1 Mägi, Reedik
A1 Pálsson, Runólfur
A1 Ostrowski, Sisse Rye
A1 Werge, Thomas
A1 Hoffart, Asle
A1 Porteous, David J
A1 Fang, Fang
A1 Jakobsdóttir, Jóhanna
A1 Lehto, Kelli
A1 Andreassen, Ole A
A1 Pedersen, Ole B. V.
A1 Aspelund, Thor
A1 Valdimarsdóttir, Unnur Anna
YR 2021
UL http://medrxiv.org/content/early/2021/12/15/2021.12.13.21267368.abstract
AB BACKGROUND The aim of this multinational study was to assess the development of adverse mental health symptoms among individuals diagnosed with COVID-19 in the general population by acute infection severity up to 16 months after diagnosis.METHODS Participants consisted of 247 249 individuals from seven cohorts across six countries (Denmark, Estonia, Iceland, Norway, Scotland, and Sweden) recruited from April 2020 through August 2021. We used multivariable Poisson regression to contrast symptom-prevalence of depression, anxiety, COVID-19 related distress, and poor sleep quality among individuals with and without a diagnosis of COVID-19 at entry to respective cohorts by time (0-16 months) from diagnosis. We also applied generalised estimating equations (GEE) analysis to test differences in repeated measures of mental health symptoms before and after COVID-19 diagnosis among individuals ever diagnosed with COVID-19 over time.FINDINGS A total of 9979 individuals (4%) were diagnosed with COVID-19 during the study period and presented overall with a higher symptom burden of depression (prevalence ratio [PR] 1·18, 95% confidence interval [95% CI] 1·03-1·36) and poorer sleep quality (1·13, 1·03-1·24) but not with higher levels of symptoms of anxiety or COVID-19 related distress compared with individuals without a COVID-19 diagnosis. While the prevalence of depression and COVID-19 related distress attenuated with time, the trajectories varied significantly by COVID-19 acute infection severity. Individuals diagnosed with COVID-19 but never bedridden due to their illness were consistently at lower risks of depression and anxiety (PR 0·83, 95% CI 0·75-0·91 and 0·77, 0·63-0·94, respectively), while patients bedridden for more than 7 days were persistently at higher risks of symptoms of depression and anxiety (PR 1·61, 95% CI 1·27-2·05 and 1·43, 1·26-1·63, respectively) throughout the 16-month study period.CONCLUSION Acute infection severity is a key determinant of long-term mental morbidity among COVID-19 patients.Competing Interest StatementCompeting interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: This work was primarily supported with grants from Nordforsk (CovidMent, 105668) and Horizon2020 (CoMorMent, 847776). AM has received speakers' fees from Illumina and Janssen and has received research grant funding from The Sackler Trust outside of the current work. OAA has received a grant to the institution from Nordforsk and Research Council of Norway for the present manuscript. OAA has also received a grant to the institution for an entity other than the present manuscript from South East Norway Health Authority, KG Jebsen Stiftelsen, and NIH, EU. OAA has received royalties for a textbook in psychiatry, consulting fees from HealthLytix and Milken Inst, payment for lectures from Sunovion and Lundbeck, and payment for expert testimony from the Norwegian Court. Outside of this work OAA has a patent for a devise for nasal delivery. OAA has participated at his institution on boards for local PI Clinical Trial Janssen, local PI Clinical Trial MAPS, and Local PI Clinical Trial Boehringer. UAV has received grants for the current work from Nordforsk and Horizon2020 as well as grants outside the current work from the Icelandic Research Fund, Swedish Research Council, Swedish Cancer Society and the European Research Council. All other authors declare no conflict of interest.Funding StatementThis work was primarily supported with grants from Nordforsk (CovidMent, 105668) and Horizon2020 (CoMorMent, 847776). EU H2020, CoMorMent, Nordforsk #CovidMent Karina Banasik acknowledges the Novo Nordisk Foundation (grants NNF17OC0027594 and NNF14CC0001) Helga Ask and Ragnar Nesvag were supported by the Research Council of Norway (RCN 324 620), Per Magnus, Lill Trogstad and the MoBa Covid-19 data collection were supported by RCN (312 721), and Ole Andreassen was supported by RCN (273 291, 223 273). Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006] and is currently supported by the Wellcome Trust [216767/Z/19/Z]. Recruitment to the CovidLife study was facilitated by SHARE- the Scottish Health Research Register and Biobank. SHARE is supported by NHS Research Scotland, the Universities of Scotland and the Chief Scientist Office of the Scottish Government. The research in the Estonian Biobank was supported by the European Union through the European Regional Development Fund (project no. 2014-2020.4.01.15-0012), and the Estonian Research Council through grant no. PSG615, the programme Mobilitas Pluss (MOBTP142), funding of Estonian sub-project of NordForsk project no. 105668, and National Programme for Addressing Socio-Economic Challenges through R&D (RITA), supported by the Estonian Government and European Regional Development Fund (RITA1/02-112). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Danish Blood Donor Study (DBDS) was approved by the Zealand and Central Denmark Regional Committees on Health Research Ethics (Den Videnskabsetiske Komite for Region Sjaelland and De Videnskabsetiske Komiteer for Region Midtjylland), Alleen 15, Soro and Skottenborg 26, Viborg (SJ-740 and 1-10-72-95-13) and the Danish Data Protection Agency (Datatilsynet), Carl Jacobsens Vej 35, Valby (P-2019-99). The Estonian Biobank cohort (EstBB-C19) was approved by the Estonian Committee on Bioethics and Human Research (Eesti bioeetika ja inimuuringute noukogu), Suur-Ameerika 1, 10122 Tallinn at Ministry of Social Affairs, Republic of Estonia (1.1-12/1277 and 1.1-12/2860). The Icelandic COVID-19 National Resilience Cohort (C-19 Resilience) was approved by the Icelandic National Bioethics Committee (Visindasidanefnd), Borgartun 21, Reykjavik (20-073 and 21-071) and Icelandic National Data Protection Authority (Personuvernd), Raudararstig 10, Reykjavik, Iceland. The Norwegian COVID-19, Mental Health and Adherence Project (MAP-19) was approved by the Regional Committee for Medical Research Ethics (Regionale komiteer for medisinsk og helsefaglig forskningsetikk), Gullhaugveien 1-3, Oslo in Norway (reference number: 125510) and Norwegian Centre for Research Data (Norsk senter for forskningsdata), Harald Harfagres gate 29, Bergen, Norway (reference number: 802810). The Norwegian Mother, Father and Child Cohort Study (MoBa) was approved by The Regional Committee for Medical and Health Research Ethics (Regionale komiteer for medisinsk og helsefaglig forskningsetikk), Gullhaugveien 1-3, Oslo in Norway (127708/14140/20138). This also includes approval to link the MoBa data with data from national health registries (including psychiatric and COVID-19 diagnostic information). The Omtanke2020 study has been registered and approved by Swedish National Ethics Board (Etikprovningsmyndigheten), Box 2110, 750 02 Uppsala (DNR 2020-01785). The CovidLife study was reviewed and given a favourable opinion by the East of Scotland Research Ethics Committee in Dundee, Scotland (Reference: 20/ES/0021, AM02, AM04, AM05, AM11).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe individual-level data underlying this article were subject to ethical approval and cannot be shared publicly due to data protection laws in each participating country.